HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetics Diversified Stock Analysis: 1999

This article was originally published in The Rose Sheet

Executive Summary

1999 Performance Of Toiletries, Fragrances And Skin Care Stocks (11 Cosmetics and 10 Diversifieds) Used In "The Rose Sheet" Index: High, Low And Close For The Yea

You may also be interested in...

Avon CEO Selection, Growth Plan Sparks 33% Fourth Quarter Stock Runup

Avon's much-anticipated appointment of Andrea Jung to CEO coupled with her unveiling of the direct-seller's forward-looking business plan made the stock an eleventh-hour winner on Wall Street in 1999.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts